Drug data last refreshed 31m ago · AI intelligence enriched 2w ago
VOLTAREN is a delayed-release oral tablet containing diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) approved in 1988. It is indicated for inflammatory and pain conditions, working by inhibiting prostaglandin synthesis through COX inhibition. The product is a mature, well-established small molecule currently approaching loss of exclusivity.
As a mature asset with moderate competitive pressure (30/100), the brand team is likely focused on defending market share through cost management and niche positioning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.
Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery
Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium
An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS
Worked on VOLTAREN at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on VOLTAREN offers exposure to mature-asset stewardship and generic-competitive dynamics in a heavily genericized market. Career value lies in defending market position, optimizing pricing strategy, and navigating the transition to post-LOE operations rather than launching or scaling growth.